Compare MATV & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MATV | ASMB |
|---|---|---|
| Founded | 1995 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 494.1M | 442.9M |
| IPO Year | 1996 | 2010 |
| Metric | MATV | ASMB |
|---|---|---|
| Price | $9.34 | $30.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $44.20 |
| AVG Volume (30 Days) | ★ 325.7K | 125.5K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.24% | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.97 | N/A |
| Revenue Next Year | $4.20 | $638.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.46 | $13.13 |
| 52 Week High | $15.48 | $39.71 |
| Indicator | MATV | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 50.37 | 57.87 |
| Support Level | $8.02 | $26.50 |
| Resistance Level | $9.99 | $30.58 |
| Average True Range (ATR) | 0.42 | 1.55 |
| MACD | -0.00 | 0.36 |
| Stochastic Oscillator | 60.86 | 71.79 |
Mativ Holdings Inc is a leader in specialty materials, solving its customers' complex challenges by engineering bold, inventive solutions that connect, protect, and purify the world. The company operates in two segments, namely Filtration & advanced Materials, focused on filtration media and components, developed films, coating and converting solutions, and extruded mesh products, and (2) Sustainable & Adhesive Solutions (SAS), focused on tapes, labels, liners, specialty paper, packaging, and healthcare solutions.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.